A5043869708- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis B Virus Studies
- Organ Transplantation Techniques and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Hepatitis C virus research
- Cancer, Hypoxia, and Metabolism
- Renal cell carcinoma treatment
- Liver physiology and pathology
- Liver Diseases and Immunity
- Lung Cancer Treatments and Mutations
- Medical Imaging and Pathology Studies
- COVID-19 Clinical Research Studies
- vaccines and immunoinformatics approaches
- Pancreatic and Hepatic Oncology Research
- Renal Transplantation Outcomes and Treatments
- Advanced Radiotherapy Techniques
- Long-Term Effects of COVID-19
- Colorectal Cancer Treatments and Studies
- Innovations in Medical Education
- Transplantation: Methods and Outcomes
- RNA Interference and Gene Delivery
Navarre Institute of Health Research
2015-2025
Clinica Universidad de Navarra
2016-2025
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2015-2025
Universidad de Navarra
2004-2024
Centro de Investigación Biomédica en Red
2008-2023
Instituto de Salud Carlos III
2011-2022
NIHR Clinical Research Network
2019
Lymphatic Education & Research Network
2019
Centre for Biomedical Network Research on Rare Diseases
2015
Freeman Hospital
2014
Most patients with hepatocellular carcinoma (HCC) have associated chronic liver disease, the severity of which is currently assessed by Child-Pugh (C-P) grade. In this international collaboration, we identify objective measures function/dysfunction that independently influence survival in HCC and then combine these into a model could be compared conventional C-P grade.We developed simple to assess function, based on 1,313 all stages from Japan, involved only serum bilirubin albumin levels....
A multicenter analysis was conducted to evaluate the main prognostic factors driving survival after radioembolization using yttrium-90-labeled resin microspheres in patients with hepatocellular carcinoma at eight European centers. In total, 325 received a median activity of 1.6 GBq between September 2003 and December 2009, predominantly as whole-liver (45.2%) or right-lobe (38.5%) infusions. Typically, were Child-Pugh class (82.5%), had underlying cirrhosis (78.5%), good Eastern Cooperative...
To the authors' knowledge, liver damage after radioembolization with yttrium90-labeled microspheres has never been studied specifically.Using a complete set of data recorded prospectively among all patients without previous chronic disease treated by at institution from September 2003 to July 2006, patterns were identified and possible risk factors analyzed.In all, 20% developed distinct clinical picture that appeared 4 8 weeks treatment was characterized jaundice ascites. Veno-occlusive...
•The incidence of coronavirus disease 2019 (COVID-19) is higher in liver transplant patients.•Mortality rates are lower than those observed the matched general population.•Immunosuppression withdrawal may not be justified.•Mycophenolate increase risk severe COVID-19 a dose-dependent manner.•Calcineurin inhibitors and everolimus deleterious for COVID-19. Background & AimsThe outcomes immunocompromised patients matter debate.MethodsWe performed prospective nationwide study including...
Radioembolization (RE)-induced liver disease (REILD) has been defined as jaundice and ascites appearing 1 to 2 months after RE in the absence of tumor progression or bile duct occlusion. Our aims were study incidence REILD a large cohort patients impact series changes introduced processes treatment design, activity calculation, routine use ursodeoxycholic acid low-dose steroids (modified protocol). Between 2003 2011, 260 with tumors treated by studied (standard protocol: 75, modified 185)....
Application of curative therapy for hepatocellular carcinoma is crucially dependent on underlying liver function. Using the recently described ALBI grade we examined long-term impact dysfunction survival early-stage (HCC) patients. This cohort study comprised 2559 HCC patients from different geographic regions, all treated with intent. We also relation between indocyanine green (ICG) clearance and score. Survival was measured date treatment to death or last follow-up. The score correlated...
Early and differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) hepatocellular carcinoma (HCC) by noninvasive methods represents a current clinical challenge. The analysis low‐molecular‐weight metabolites new high‐throughput techniques is strategy for identifying biomarkers. Here, we have investigated whether serum metabolome can provide useful biomarkers in the iCCA HCC could discriminate from HCC. Because primary sclerosing cholangitis (PSC) risk factor CCA, metabolic profiles...
To compare selective internal radiation therapy (SIRT) with transarterial chemoembolization (TACE), the standard-of-care for intermediate-stage unresectable, hepatocellular carcinoma (HCC), as first-line treatment.SIRTACE was an open-label multicenter randomized-controlled pilot study, which prospectively compared primarily safety and health-related quality of life (HRQoL) changes following TACE SIRT. Patients unresectable HCC, Child-Pugh ≤B7, ECOG performance status ≤2 ≤5 liver lesions (≤20...
Milan criteria are the most frequently used limits for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC), but our previous experience expanded showed encouraging results. The aim of this study was to investigate whether Clinica Universitaria de Navarra (CUN) (1 nodule up 6 cm or 2–3 nodules 5 each) could be select HCC LT. Eighty-five fulfilling CUN were included as candidates Survival transplanted compared survival without (n = 180). After exclusion 2 tumor seeding...
Abstract Purpose: Immunotherapy for hepatocellular carcinoma (HCC) shows considerable promise in improving clinical outcomes. HepaVac-101 represents a single-arm, first-in-human phase I/II multicenter cancer vaccine trial HCC (NCT03203005). It combines multipeptide antigens (IMA970A) with the TLR7/8/RIG I agonist CV8102. IMA970A includes 5 HLA-A*24 and 7 HLA-A*02 as well 4 HLA-DR restricted peptides selected after mass spectrometric identification human tissues or cell lines. CV8102 is an...
To evaluate the safety and efficacy of selective internal radiation therapy (SIRT) in combination with a PD-1 inhibitor patients unresectable hepatocellular carcinoma (uHCC) liver-only disease ineligible for chemoembolization.NASIR-HCC is single-arm, multicenter, open-label, phase 2 trial that recruited from 2017 to 2019 who were naïve immunotherapy had tumors BCLC B2 substage (single or multiple beyond up-to-7 rule), unilobar segmental lobar portal vein invasion (PVI); no extrahepatic...
New prognostic markers are needed to identify patients with hepatocellular carcinoma (HCC) who carry a worse prognosis. Ultra-low-pass whole-genome sequencing (ULP-WGS) (≤0.5× coverage) of cell-free DNA (cfDNA) has emerged as low-cost promising tool assess both circulating tumor (ctDNA) fraction and large structural genomic alterations. Here, we studied the performance ULP-WGS plasma cfDNA infer prognosis in HCC. Plasma samples were obtained from HCC prior surgery, locoregional or systemic...
Liver transplant recipients have an increased risk of malignancy. Smoking is related to some the most frequent causes posttransplant The incidence and factors for development neoplasia smoking (head neck, lung, esophageal, kidney urinary tract carcinomas) were studied in 339 liver recipients. Risk smoking-related also 135 patients who had a history so that it could be determined whether withdrawal was associated with lower After mean follow-up 7.5 years, 26 diagnosed 29 malignancies. 5-...